ERBB2 and breast carcinoma: Furthermore, upon trastuzumab treatment, the more DPAGT1 was expressed in HER2+ breast cancer cells, the more DPAGT1 protein would be retrogradely transported from the plasma membrane to the ER (Supplemental Figure 4C).